AbbVie Inc. (ABBV)
What changed in recent filings
- Institutions — 3 new · 1 added · 2 reduced13F · as of end of 2026 Q2
- Free cash flow declined recentlyDec 31, 2025 → Jun 30, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
AbbVie Inc. recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 31, 2026Revenue +10.2% YoY · EPS $2.03Released before the open: Jul 30 close → Jul 31 close, the stock moved -2.5% · over the same window, market +0.7% · sector -0.5%
- 26Q1Released Apr 29, 2026Revenue +12.4% YoY · EPS $0.39Released before the open: Apr 28 close → Apr 29 close, the stock moved +3.1% · over the same window, market +0.0% · sector -1.2%
- 25Q4Released Feb 4, 2026Revenue +10.0% YoY · EPS $1.02Released before the open: Feb 3 close → Feb 4 close, the stock moved -3.8% · over the same window, market -0.5% · sector +0.1%
- 25Q3Released Oct 31, 2025Revenue +9.1% YoY · EPS $0.10Released before the open: Oct 30 close → Oct 31 close, the stock moved -4.5% · over the same window, market +0.3% · sector +0.0%
The next earnings release is estimated around Oct 30, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding AbbVie Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 5 → 2026 Q2: 9 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold AbbVie Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.65% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.59% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.01% of portfolio · since 2021 Q2
- Capital World Investors0.57% of portfolio · since 2022 Q3
- Harris Associates (Oakmark)under 0.01% of portfolio · since 2025 Q2
- Point72 Asset ManagementNew this quarter0.10% of portfolio · since 2026 Q2
- GQG PartnersNew this quarter0.90% of portfolio · since 2026 Q2
- Glenview Capital ManagementNew this quarter0.68% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
A pharma company overcoming the patent cliff of its autoimmune drug Humira by successfully launching successors Skyrizi and Rinvoq.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
AbbVie Inc. is classified under the Biotech & Health sector. See peers below.
AbbVie Inc. key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
AbbVie Inc. vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
ABBV segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding AbbVie Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
ABBV on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
ABBV FAQ
What is AbbVie Inc. (ABBV)?
A pharma company overcoming the patent cliff of its autoimmune drug Humira by successfully launching successors Skyrizi and Rinvoq.
What sector is AbbVie Inc. in?
AbbVie Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are AbbVie Inc.'s key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 10.4%, Operating margin 37.9%, Net margin 9.8%. Definitions and interpretation are available on Stocklore.
Where can I analyze AbbVie Inc. (ABBV) stock?
On Stocklore you can see ABBV's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.